“Biosimilars, dominated by global pharma players, is forecasted to expand at a compounded average growth rate of 12 per cent in Asia”
China remains an attractive destination for MNCs and regionals pharma players for biosimilars development. Risks are reduced through strategic alliances and partnerships with local Chinese manufacturers.
IBC’s Biosimilars Asia 2014, the largest and most cutting-edge conference will this year focus on partnerships and emerging models of collaboration that provide win-win solutions for regional biosimilar companies and MNCs.
Find out regulatory updates and emerging partnership models that align capabilities and business objectives.
“The future of biosimilars is quite promising with over 63 billion dollars global biologic sales products due to come off patent by 2016.”
- Asia Biotech 2013
Collaborative Development and Successful Commercialisation
While partnering with local China companies can bring economies of scale, market knowledge and better networks, there are also learning opportunities from partnering with MNCs in terms of quality assurance, improved R&D processes and technology transfer.
IBC’s 5th Annual Biosimilars Asia will bring together senior level biosimilar development, manufacturing and commercialization decision makers from Asia and globally. It provides an unrivalled platform to find solutions to the most pressing strategic challenges as well as innovations in the development of biosimilars.
Mark your calendars now and be part of the biggest biosimilars conference in Asia to establish and renew partnerships to develop new products, acquire new process technologies and establish more effective biomanufacturing relationships.
The Biopharma Development & Production Week is the leading industry platform for pharma, biotech, CMOs, CROs, research institutes, investors and industry stakeholders to meet, network and discuss current industry trends, establish business partnerships and be updated on investment opportunities in China and surrounding Asia. For more information visit www.biopharmaproduction.com
|The conference will be conducted in English.
No simultaneous translation is provided.
|Groups of 3 or more benefit from DISCOUNTED RATES!
Groups of 3 – Each delegate SAVES USD 500 off
the normal rate!
Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member
European Medicines Agency
| Li Cai
Regional R&D Counsel
| Dr Shaligram Rane
Vice President for Quality
Intas Pharmaceuticals, India
| Dr Victoria Elegant
VP Medical & Regulatory Affairs
| Jeremy Caudill
Global Vice President Business Development
Samsung Biologics, Korea
| Jianguo Yang
Sanofi Genzyme, USA
| Sameer Agarwal
Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions
Fresenius Kabi Deutschland GmbH, Germany
|Dr. Raymond De Vre
Vice President Biologics
Dr. Reddy's Laboratories, Switzerland
To view speakers list »
- Revamped agenda featuring never-before heard speakers with focus on successful partnering models and clinical development
- Co-located with Cell Line Development and Engineering Asia and Biomanufacturing 2014 bringing together an expanded network of Biologics R&D thought-leaders and biomanufacturing players
- Interactive format including roundtables, more panel discussions and speed networking for improved business deal making
- Hear new case studies from the region including Malaysia, Korea and Taiwan
- Featuring insights into conducting biosimilars trials, assessing immunogenicity and pharmacovigilance
- Multi-speaker pre-conference workshop on Clinical Development for Biosimilars
Good updates on the biosimilars market and regulations
– Esteve Quinica
Great insight into global thought processes on biosimilar development.
I walked away with an indepth understanding of trends in biologies/biosimilars, regulatory hurdles and market access.